News Home

Press Releases

Subscribe




RECEIVE LANTHEUS MEDICAL IMAGING SUPPLY UPDATES EMAILS











MOLY UPDATE
3/04/10 Update on Lantheus Commitment during Molybdenum-99 Shortage
12/30/09 Update on Lantheus Commitment during Molybdenum-99 Shortage
8/13/09 Lantheus Response to the Announcement by AECL that the NRU Reactor Will Not Be Restarted Until 2010
7/21/09 Update on Lantheus Commitment during Molybdenum-99 Shortage
6/13/09 Lantheus Commitment during Molybdenum-99 Shortage


Important Safety Information for TechneLite®:

Allergic reactions including anaphylaxis have been reported infrequently.

Please See Full Prescribing Information

Important Safety Information for Cardiolite®:

Indications and Usage:  
Cardiolite®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (eg, exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling).

It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia.

Important Safety Information:
Exercise and pharmacologic stress testing should be performed only under the supervision of a qualified physician. Cardiolite® has been rarely associated with acute severe allergic events of angioedema and urticaria. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Please See Full Prescribing Information

 


© 2010 Lantheus Medical Imaging, Inc.